Commense Health

Commense Health is a biotechnology company dedicated to developing microbiome-derived therapies for the prevention and treatment of pediatric diseases. Originally founded by PureTech Health, the company focuses on the maternal-to-infant microbiome, aiming to restore beneficial microbes that are often missing in children born via Cesarean section. Their research centers on the critical early-life window where the microbiome shapes the developing immune system. Commense's pipeline includes live biotherapeutic products designed to prevent conditions such as asthma, allergies, and atopic dermatitis. In early 2023, the company was acquired by ExeGi Pharma, a leader in probiotic and microbiome-based treatments, to further the development of these infant-focused therapies.